FREE WHITEPAPER
Bridging Studies for AAV Producer Cell Line Adoption
Regulatory and development perspectives on when and how to move from transient transfection to a stable Producer Cell Line for AAV gene therapy manufacturing
As AAV gene therapies expand beyond rare-disease indications toward higher doses and broader patient populations, manufacturing efficiency, consistency and scalability are becoming commercial necessities, not just technical goals.
This white paper lays out the regulatory and development considerations behind switching from transient transfection to a stable Producer Cell Line and why the timing of that switch has a direct effect on the comparability and bridging studies a program will need.
What’s inside:
Why AAV manufacturing must evolve: The yield, cost, and variability limits of transient transfection and why they become barriers as AAV programs move into more prevalent indications.
Producer cell lines make a difference: How stable PCLs simplify supply chains, reduce raw material costs, and bring AAV manufacturing closer to mature biologics processes.
Comparability & bridging studies: How ICH Q5E principles and EMA/FDA guidance frame the switch as a manufacturing process change, and what triggers additional nonclinical or clinical data.
Why timing of the transition matters: Why switching as early as possible — ideally before or during Phase 1 — minimizes the comparability burden and the risk to established safety data.
Robust analytics as the foundation: The extended characterization, potency/infectivity and stability assays that underpin a defensible comparability package.
Xcite® AAV Stable Producer Cell Line: A look at Lonza’s PCL platform technology, its demonstrated productivity and stability data, and how it’s deployed via licensing or outsourced development.
Download your copy today